The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life

被引：11
作者：
Bomalaski, JJ [1 ]
机构：
[1] Univ S Florida, Coll Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Tampa, FL 33606 USA
来源：
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 1999年 / 11卷 / 01期
关键词：
D O I：
10.1097/00001703-199901000-00003
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Despite an increasing number of studies utilizing various agents and protocols, the disease free interval and survival rates in patients with recurrent ovarian cancer are usually measured in months instead of years. The optimal therapy strategy should be determined using informed decisions based on realistic treatment outcomes, quality of life issues, and cost containment. Curr Opin Obstet Gynecol 11:11-15. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码：11 / 15
页数：5
相关论文
共 38 条
  • [1] ABURUSTUM NR, 1997, SEMIN ONCOL S15, V24, pS1562
  • [2] RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS
    BLACKLEDGE, G
    LAWTON, F
    REDMAN, C
    KELLY, K
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (04) : 650 - 653
  • [3] Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy
    Blom, R
    Palm, N
    Simonsen, E
    [J]. ACTA ONCOLOGICA, 1996, 35 (06) : 733 - 736
  • [4] Long-term survival with whole abdominopelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer
    Cmelak, AJ
    Kapp, DS
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 65 (03) : 453 - 460
  • [5] Alternative care - Patient choices for adjunct therapies within a cancer center
    Coss, RA
    McGrath, P
    Caggiano, V
    [J]. CANCER PRACTICE, 1998, 6 (03) : 176 - 181
  • [6] Dancey J, 1997, QUAL LIFE RES, V6, P151
  • [7] Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer
    deJong, RS
    Hofstra, LS
    Willemse, PHB
    deBruijn, HWA
    deVries, EGE
    Boonstra, H
    Mulder, NH
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 66 (02) : 197 - 201
  • [8] Resource implications of palliative chemotherapy for ovarian cancer
    Doyle, C
    Stockler, M
    Pintilie, M
    Panesar, P
    Warde, P
    Sturgeon, J
    Oza, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1000 - 1007
  • [9] FOLEY K, 1997, CANC PRINCIPLES PRAC
  • [10] Foltz A, 1996, J Cancer Educ, V11, P32
1234